- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02892071
Tri-split Face Study of Skin Resurfacing Modalities for the Treatment of Melasma
March 23, 2020 updated by: SUZAN OBAGI
Tri-split face study of skin resurfacing modalities for the treatment of melasma, comparing the medium depth trichloroacetic acid peel, CO2 laser and Qs-NdYag laser.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Melasma is an acquired chronic and relapsing hyperpigmentation disorder, with a significant negative impact on the quality of life of patients.
Melasma is more common in patients with skin of color and has also been linked to chronic ultraviolet (UV) and heat exposure, family history and hormonal factors.
There are several studies in the literature using various therapies for melasma, including sun protection, topical therapies, lasers and chemical peels.
However, many of these studies vary greatly in their efficacies and side effect profiles, due to varying and undelineated pre and post-op procedure regimens.
Side effects of post-inflammatory hyper and hypopigmentation and rebound are reported in these studies.
The investigators would like to conduct a tri-split face study that compares a 22% trichloroacetic acid (TCA) deep medium peel with an ablative fractionated CO2 laser and more pigment selective Q-switched (Qs) Nd:YAG laser.
To minimize possible post-procedure side effects and melasma rebound, the investigators will perform above treatments in conjunction with an optimal skincare regimen, starting 6 weeks before and continuing after the treatments.
The investigators will perform the 22% TCA chemical peel, CO2 laser and Qs-Nd:YAG at 6 weeks after the start of the skincare regimen, and repeat treatments with Qs-Nd:YAG at weeks 8, 10, and 12.
The investigators will assess participants using standardized photos in conjunction with UV imaging (Visia CR) at weeks 0, 6, 16, 20 and 24 (6 months), by measuring the modified melasma area and severity index (mMASI) scores and visual analog scale (VAS) scores as graded by participants as well as by blinded physicians based on photos and UV imaging.
Study Type
Interventional
Phase
- Phase 1
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 60 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- male or female participants
- 20 to 60 years old
- participants with melasma on forehead and both cheeks
- participants who failed topical therapy for melasma
- participants who have never tried other therapies for melasma
Exclusion Criteria:
- pregnancy
- lactation
- use of oral contraceptive (OCP) within 3 months of starting the study
- hormonal therapy within 3 months of starting the study
- hormonal intrauterine device (IUD) within 3 months of starting the study
- history of poor wound healing or abnormal scarring
- history of lip or face herpes simplex virus infections
- active facial skin infection
- history of connective tissue disorders (such as lupus or scleroderma)
- history of isotretinoin therapy within 6 months of starting the study
- history of chemical peels, dermabrasion, laser therapy or intense pulse light (IPL) within 6 months before enrollment into the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 22% TCA peel
22% trichloroacetic acid medium depth chemical peel applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)
|
One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel).
Each treatment will take about 20 minutes.
A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.
Other Names:
|
Active Comparator: CO2 laser
CO2 ablative fractional laser resurfacing applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek)
|
One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will receive one treatment with one pass of the fractionated ablative 10,600 nm CO2 (CO2RE Laser, Syneron) at Core 70 mJ, Ring 50mJ, 40% coverage, 1 pass, 8 mm square pattern.
Each treatment will take about 20 minutes.
Other Names:
|
Active Comparator: Qs-NdYAG laser
Long pulsed Q-switched Nd:Yag laser will be applied to one of the three facial areas (based on random assignment- forehead, left cheek, right cheek), performed at 2-week intervals for six sessions.
|
Long pulsed Q-switched Nd:Yag laser.
One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with Q-switched (Qs) 1064 Nd:YAG (Medlite C3; 6 mm spot size, collimated homogenous flat- top beam profile, energy fluence 2.0 J/cm2, 5Hz), with 5% coverage and 2 passes (or until mild erythema detected).
Treatments will be performed at 2-week intervals for six sessions.
Each treatment will take about 20 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
modified melasma area and severity index (mMASI) score
Time Frame: 6 months
|
score calculated by measuring darkness of pigment of melasma patch area
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
visual analog scale (VAS) assessment by physicians
Time Frame: 6 months
|
CR
|
6 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
participant satisfaction assessment
Time Frame: 6 months
|
Participants will score their satisfaction with improvement for each modality
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Suzan Obagi, MD, University of Pittsburgh Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Moubasher AE, Youssef EM, Abou-Taleb DA. Q-switched Nd: YAG laser versus trichloroacetic acid peeling in the treatment of melasma among Egyptian patients. Dermatol Surg. 2014 Aug;40(8):874-82. doi: 10.1097/DSS.0000000000000065.
- Trelles MA, Velez M, Gold MH. The treatment of melasma with topical creams alone, CO2 fractional ablative resurfacing alone, or a combination of the two: a comparative study. J Drugs Dermatol. 2010 Apr;9(4):315-22.
- Jalaly NY, Valizadeh N, Barikbin B, Yousefi M. Low-power fractional CO(2) laser versus low-fluence Q-switch 1,064 nm Nd:YAG laser for treatment of melasma: a randomized, controlled, split-face study. Am J Clin Dermatol. 2014 Aug;15(4):357-63. doi: 10.1007/s40257-014-0080-x.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
December 1, 2020
Primary Completion (Anticipated)
September 1, 2022
Study Completion (Anticipated)
September 1, 2022
Study Registration Dates
First Submitted
August 23, 2016
First Submitted That Met QC Criteria
September 1, 2016
First Posted (Estimate)
September 8, 2016
Study Record Updates
Last Update Posted (Actual)
March 25, 2020
Last Update Submitted That Met QC Criteria
March 23, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRO15090113
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melasma
-
Mesoestetic Pharma Group S.L.Completed
-
ConBio, a Cynosure CompanyCompleted
-
University of Nove de JulhoRecruiting
-
Jinnah Postgraduate Medical CentreActive, not recruiting
-
China Medical University HospitalCompleted
-
VIST - Faculty of Applied SciencesActive, not recruiting
-
China Medical University HospitalApollo Medical Optics, LtdCompleted
-
Combined Military Hospital AbbottabadCompleted
-
Northwestern UniversityCompleted
-
Centre Hospitalier Universitaire de NiceCompleted
Clinical Trials on 22% TCA peel
-
Loyola UniversityCompleted
-
Nova Scotia Health AuthorityRecruiting
-
Assiut UniversityNot yet recruiting
-
Allotex, Inc.WithdrawnHyperopiaAustria, Belgium, France, Ireland, Switzerland, United Kingdom
-
Henry Ford Health SystemCompletedPost-inflammatory HyperpigmentationUnited States
-
Allotex, Inc.TerminatedPresbyopiaBelgium, Ireland, United Kingdom
-
Peel Therapeutics IncRecruitingAdvanced Solid TumorUnited States
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...CompletedArsenical KeratosisBangladesh
-
Allotex, Inc.WithdrawnSafety and Efficacy of a Sub-epitheilal Transform™ Corneal Allograft (TCA) for Presbyopia CorrectionRefractive Errors | PresbyopiaAustria, Belgium, France, Ireland, Switzerland, United Kingdom
-
Medical University of South CarolinaJohns Hopkins University; University of North Carolina; Cook Endoscopy; Thoraxklinik-Heidelberg...CompletedQuantity of Tissue Obtained | Quality of Tissue Obtained | Ease of Use of 22-gauge ProCore EBUS Needles and the Standard 22-gauge NeedlesUnited States